Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCloudtag Inc Regulatory News (CTAG)

  • There is currently no data for CTAG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

30 May 2014 16:00

RNS Number : 5093I
CloudTag Inc.
30 May 2014
 



30 May 2014

CloudTag Inc.("CloudTag" or the "Company")

Half Year Results

for the six month period ended 31 March 2014

 

CloudTag (CTAG:LN), which develops personal performance monitoring for the professional sports and consumer well being markets, is pleased to announce its interim results for the six months ended 31 March 2014.

 

Summary of H1 2014 and current trading update

 

· Completion of user testing and launch of the 'mycloudtag' app on iOS App Store post period end

· Hardware development continuing in collaboration with our technology partners

 

· Manufacturing partner identified for mass production of CloudTag's first wearable device

· Successfully completed placing of £500,000 post period end

 

The accounts for the six months ended 31 March 2014 will shortly be available at the Company's website, http://www.cloudtag.com, in accordance with AIM Rule 20.

 

Andy Jackson, CEO, commented:

"I am delighted to announce the launch of our first product. This is a significant milestone and has moved the Company from pure development to initial revenue generation. I look forward to more users downloading the 'mycloudtag' app and the launch, later this year, of both Cloud architecture and our wearable device which is intended to provide an innovative and integrated experience far superior to that available in the current retail marketplace."

 

Enquiries:

 

CloudTag Inc.

Andy Jackson / Jamie Bligh

 

+44 (0) 20 3740 7464

contact@cloudtag.com

Strand Hanson Limited (Nominated & Financial Adviser)

James Harris / James Spinney / Ritchie Balmer

 

+44 (0) 20 7409 3494

Gable Communications Limited

John Bick / Justine James

+44 (0) 20 7193 7463

+44 (0) 7872 061 007

cloudtag@gablecommunications.com

 

 

 

Chairman's Statement

 

I am delighted that we have recently launched our stand-alone user interface and mobile application, "mycloudtag" (the "App"), which has been developed in collaboration with our software partner Preciousbluedot Ltd. The App is available for free download from Apple Incorporated's App Store and we are working hard to bring the App to Google's Android Platform. Paid-for premium programmes and monthly subscriptions are available for users looking to fast track their training, enabling them to unlock any programme at any time, and allowing the Company to begin generating revenue. The App uses cutting edge 'gamification' to create a unique user experience and delivers high quality professional wellness and sporting video content to the user's mobile device.

 

The App brings gaming DNA to fitness apps by reorienting how people interact with these applications. Rather than tracking activity and delivering data on such things as how many calories burned, distance walked or pace per mile, the App directly rewards users by giving points or 'stars' for completed programmes. The fitness and wellness programmes are set up like journeys or paths that need to be completed to get to the next level in the App. Each level that is completed gives the user points that can then be used to unlock additional content

 

The software team are now finalising the development of the Cloud architecture which will allow users to store and access information remotely from their mobile device (data is currently stored locally on the user's mobile device). This will enable the Company to introduce new features to the App in the coming months. Meanwhile, we have commenced marketing of the App with an initial focus on the UK and US markets. The introduction of our new website was the first stage in the process. We are also in advanced discussions with a number of global gym chains, health insurance companies and retailers with a view to creating fully customised Apps for these potential customers, based on the CloudTag architecture and our software development.

 

Over the past few months, we have recognised a shift in the market for wearable devices and fitness tracking. The accuracy of a number of existing devices has been brought into question and we feel it is incredibly difficult for users to get accurate information from their devices. With that in mind, I believe we are well placed with our technology and have focussed our attention on the development of our patch that utilises ECG technology, derived from clinical devices, rather than advanced accelerometer techniques currently dominant in the retail marketplace. Initial indications suggest that devices utilising ECG technology are significantly more accurate than existing wearable devices targeted at the retail/professional sports markets, particularly for heart-rate related measurements.

 

This device, once launched, will include a system for intelligent wireless body monitoring that facilitates real-time vital-sign data collection and data transfer using Bluetooth Low Energy. The devices will also have the added feature of being entirely waterproof, thereby enabling them to be used for swimming and water sports.

 

Financial Results

 

In the six months to 31 March 2014, the Group recorded a loss before and after tax of £1,012,000 (H1 2013: loss of £1,997,000). This period's loss includes certain fees settled in shares and non-recurring costs associated with product development. The Company continues to be run on a very tight cost-base and the Company's board of directors (the "Board") carefully manages all expenditure. The Board does not recommend the payment of a dividend at this time.

Placing

 

On 31 March 2014, the Company announced that it had conditionally raised gross proceeds of £500,000 through a placing of 6,250,000 Ordinary Shares of 0.1 pence each in the Company (the "Placing"). Completion of the Placing was conditional upon, inter alia, the Company obtaining approval from Shareholders to their allotment and associated disapplication of pre-emption rights at the Company's Annual General Meeting to be held on 23 April 2014 (the "AGM"). Shareholder approval was duly granted at the AGM and the Placing completed on 24 April 2014 with the issue of the 6,250,000 placing shares. Following receipt of the Placing net proceeds, and less expenditures since the period's end, the Company's current cash balance is approximately £340,000.

 

Outlook

 

The wearable technology and mobile application market continues to be very active with significant acquisitions in recent months by Under Armour, Facebook, and Intel. CloudTag has made considerable progress towards launching its innovative solutions for the fitness and wellbeing markets. We look forward to progressing towards the launch of our wearable devices alongside updates to the App. The Board believes it is an exciting time for the Company and its stakeholders.

 

 

 

Tony Reeves

Chairman

30 May 2014

 

  

 

 

CLOUDTAG INC.

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE PERIOD ENDED 31 MARCH 2014

 

Unaudited

Unaudited

Audited

Note

Period ended 31 March 2014

 Period ended 31 March 2013

Year ended 30 September 2013

£'000

£'000

£'000

Share based payments

(132)

(433)

(627)

Research and development costs

(420)

(233)

(580)

Other administrative expenses

(460)

(1,331)

(1,633)

Total administrative expenses

(1,012)

(1,997)

(2,840)

Loss from operations and loss before taxation

(1,012)

(1,997)

(2,840)

Taxation

-

-

-

Loss after taxation, total comprehensive loss for the period and loss attributable to the equity holders of the Company

(1,012)

(1,997)

(2,840)

Loss per share

Total basic and diluted (pence per share)

4

(0.68)

(1.49)

(2.01)

 

   

 

CLOUDTAG INC.

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE PERIOD ENDED 31 MARCH 2014

 

 

Share capital

Share premium

Share based payments reserve

Retained earnings

Total equity

£'000

£'000

£'000

£'000

£'000

Unaudited Balance at 30 September 2012

134

418

-

(670)

(118)

Issue of share capital

14

2,860

(400)

-

2,474

Share issue costs

-

(76)

-

-

(76)

Share based payments

-

-

434

-

434

Transactions with owners

14

2,784

34

-

2,832

Loss for the period

-

-

-

(1,997)

(1,997)

Unaudited Balance at 31 March 2013

148

3,202

34

(2,667)

717

Issue of share capital

-

-

-

-

0

Share based payments

-

-

193

-

193

Transactions with owners

-

-

193

-

193

Loss for the period

-

-

-

(843)

(843)

Audited Balance at 30 September 2013

148

3,202

227

(3,510)

67

Share based payments

-

-

132

-

132

Transactions with owners

-

-

132

-

132

Loss for the period

-

-

-

(1,012)

(1,012)

Unaudited Balance at 31 March 2014

148

3,202

359

(4,522)

(813)

 

 

 

CLOUDTAG INC.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 31 MARCH 2014

 

 

Unaudited

Unaudited

Audited

31 March 2014

31 March 2013

30 September 2013

Assets

Notes

£'000

£'000

£'000

Fixed assets

Property, plant and equipment

2

-

1

Current

Cash and cash equivalents

100

307

556

Trade and other receivables

5

11

849

5

Total current assets

111

1,156

561

Total assets

113

1,156

562

Liabilities

Current

Trade and other payables

6

926

439

495

Total liabilities

926

439

495

Equity

Issued share capital

7

148

148

148

Share premium

3,202

3,202

3,202

Share based payments reserve

359

34

227

Retained earnings

(4,522)

(2,667)

(3,510)

Equity attributable

to owners of the company

(813)

717

67

Total equity and liabilities

113

1,156

562

 

 

  

CLOUDTAG INC.

CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE PERIOD ENDED 31 MARCH 2014

 

Unaudited

Unaudited

Audited

Period ended

Period ended

Year ended

31 March 2014

31 March 2013

30 September 2013

£'000

£'000

£'000

Operating activities

Loss after tax

(1,012)

(1,997)

(2,840)

Share based payments

132

433

627

Fees paid in shares

-

950

950

Decrease/(increase) in trade and other receivables

(6)

43

102

Increase in trade and other payables

431

72

127

Net cash (outflow) from operating activities

(455)

(499)

(1,034)

Cash flows from investing activities

Purchase of property, plant and equipment

(1)

-

(1)

Net cash outflow from financing activities

(1)

-

(1)

Financing activities

Proceeds from issue of share capital

-

740

1,525

Share issue costs

-

(76)

(76)

Amounts deposited with shareholder

(550)

-

(745)

Amounts returned from shareholder

550

-

745

Net cash inflow from financing activities

-

664

1,449

Net change in cash and cash equivalents

- 456

165

414

Cash and cash equivalents at beginning of period

556

142

142

Cash and cash equivalents at end of period

100

307

556

 

 

CLOUDTAG INC.

NOTES TO THE INTERIM REPORT

FOR THE PERIOD ENDED 31 MARCH 2014

1. GENERAL INFORMATION

The financial information set out in this interim report does not constitute statutory accounts as defined in Section 434 of the Companies Act 2006. The figures for the year ended 30 September 2013 have been extracted from the 2013 statutory financial statements. The auditors' report on those accounts was unqualified and did not contain a statement under section 498 of the Companies Act 2006.

2. ACCOUNTING POLICIES

The Company's shares are quoted on the AIM market of the London Stock Exchange and the Company applies the Companies Act 2006 when preparing its annual financial statements.

The annual financial statements will be prepared under International Financial Reporting Standards as adopted by the European Union (IFRS) and the principal accounting policies adopted remain unchanged from those adopted in preparing its financial statements for the year ended 30 September 2013.

The accounting policies have been applied consistently throughout the Group for the purposes of preparation of these condensed consolidated interim financial statements.

3. SEGMENTAL REPORTING

An operating segment is a distinguishable component of the Group that engages in business activities from which it may earn revenues and incur expenses, whose operating results are regularly reviewed by the Group's chief operating decision maker to make decisions about the allocation of resources and an assessment of performance and about which discrete financial information is available.

 

The chief operating decision maker has defined that the Group's only operating segment during the period is the development of physiological technology. All of the corporate headquarter costs are allocated to this segment.

 

The Group has not generated any revenues from external customers during the period.

 

In respect of the non-current assets all arise in the UK at 31 March 2014 and 30 September 2013.

 

4. LOSS per share 

The calculation of the basic loss per share is based on the loss attributable to ordinary shareholders divided by the weighted average number of shares in issue during the period. The impact of the options and warrants on the loss per share is anti-dilutive.

 

Unaudited

Unaudited

Audited

Period ended

Period ended

Year ended

31 March 2014

31 March 2013

30 September 2013

£'000

£'000

£'000

Loss on ordinary activities after tax (£000)

(1,012)

(1,997)

(2,840)

Weighted average number of shares for calculating basic loss per share

147,775,000

134,268,819

141,040,411

Basic and diluted loss per share (pence)

(0.68)

(1.49)

(2.01)

 

 

5. trade and other receivables

Unaudited

Unaudited

Audited

31 March 2014

31 March 2013

30 September 2013

£'000

£'000

£'000

VAT recoverable

7

60

2

Prepayments

4

4

3

Unpaid share capital

-

785

-

Total

11

849

5

 

Trade and other receivables are usually due within 30 - 60 days and do not bear any effective interest rate. The fair value of these short term financial assets is not individually determined as the carrying amount is a reasonable approximation of fair value. The unpaid share capital outstanding at 31 March 2013 has been received in full.

 

6. TRADE AND OTHER PAYABLES

 

Unaudited

Unaudited

Audited

31 March 2014

31 March 2013

30 September 2013

£'000

£'000

£'000

Trade payables

371

362

145

Other payables

166

11

14

VAT payable

 -

-

-

Accruals

389

66

336

926

439

495

 

7. SHARE CAPITAL

The movement in share capital is set out below.

Unaudited

Unaudited

Audited

31 March 2014

31 March 2013

30 September 2013

£000

£000

£000

Allotted, issued and fully paid

147,775,000 ordinary shares of 0.01p (31 March 2013 and 30 September 2013: 147,775,000)

148

148

148

8. SHARE OPTIONS

The Group operates share option schemes for certain employees (including directors). Options are exercisable at the option price agreed at the date of grant. The options are settled in equity once exercised. The options are exercisable from the date the conditions are met until 10 years from the grant date. The expected life of the options varies from six months to three years.

Details of the number of share options and the weighted average exercise price ("WAEP") outstanding during the year are as follows:

Unaudited

Unaudited

Audited

31 March 2014

31 March 2013

30 September 2013

Number

WAEP

Number

WAEP

Number

WAEP

£

£

£

Outstanding at the beginning of the period

4,549,998

0.2176

-

-

-

-

Issued on 20 March 2013

-

-

4,549,998

0.2176

4,549,998

0.2176

Outstanding at the end of the period

4,549,998

0.2176

4,549,998

0.2176

4,549,998

0.2176

 

 

The options have the following exercise prices and fair values at the date of grant:

 

 

First exercise date (when vesting conditions are met)

Grant date

Exercise price

Fair value

31 March 2014

31 March 2013

30 September 2013

£

£

Number

Number

Number

20 March 2013

20 March 2013

0.2

0.1163

500,000

500,000

500,000

On launch of product if by 20 March 2014

20 March 2013

0.2

0.1163

1,100,000

1,100,000

1,100,000

On launch of product if by 20 March 2014

20 March 2013

0.25

0.10665

200,000

200,000

200,000

On launch of product if by 20 March 2014

20 March 2013

0.3

0.09862

166,666

166,666

166,666

Turnover exceeds £750,000 in a month and share price exceeds 40p for 5 consecutive days

20 March 2013

0.2

0.1163

1,100,000

1,100,000

1,100,000

Turnover exceeds £750,000 in a month and share price exceeds 40p for 5 consecutive days

20 March 2013

0.25

0.10665

200,000

200,000

200,000

Turnover exceeds £750,000 in a month and share price exceeds 40p for 5 consecutive days

20 March 2013

0.3

0.09862

166,666

166,666

166,666

Turnover exceeds £1,500,000 in a month and share price exceeds 60p for 5 consecutive days

20 March 2013

0.2

0.1163

750,000

750,000

750,000

Turnover exceeds £1,500,000 in a month and share price exceeds 60p for 5 consecutive days

20 March 2013

0.25

0.10665

200,000

200,000

200,000

Turnover exceeds £1,500,000 in a month and share price exceeds 60p for 5 consecutive days

20 March 2013

0.3

0.09862

166,666

166,666

166,666

4,549,998

4,549,998

4,549,998

 

The share options can be exercised from the date when the conditions are met until ten years from the grant date.

 

At 31 March 2014, 500,000 options were exercisable.

For those options granted to employees and directors where IFRS 2 "Share-Based Payment" is applicable, the fair values were calculated using the Black-Scholes model. The inputs into the model were as follows:

20 March 2013

Risk free rate

0.50%

Share price volatility

50%

Expected life

Between 6 months and 3 years

Share price at date of grant

£0.20

 

Expected volatility was determined by calculating the historical volatility of the share price of a similar AIM listed company. The expected life used in the model has been adjusted, based on management's best estimate, for the effects of non-transferability, exercise restrictions and behavioural considerations.

The following assumptions were used:

The options granted on 20 March 2013, exercisable on launch of the product provided that this is within 12 months of admission, were assumed to vest in 12 months.

The options granted on 20 March 2013, exercisable immediately, were assumed to vest in 6 months as the share price was expected to rise above 20p by that time.

The options granted on 20 March 2013, exercisable when turnover exceeds £750,000 in a month and the share price exceeds 40p for five consecutive days, were assumed to vest in 24 months.

The options granted on 20 March 2013, exercisable when turnover exceeds £1,500,000 in a month and the share price exceeds 60p for five consecutive days, were assumed to vest in 36 months.

The Group recognised a charge of £132,000 (period ending 31 March 2013 £34,000 and year ended 30 September 2013: £227,000) relating to these equity-settled share-based payment transactions during the period.

9. CONTINGENT LIABILITIES

At 31 March 2014, 31 March 2013 and 30 September 2013 there were no contingent liabilities.

 

10. EVENTS AFTER THE REPORTING DATE

 

On 7 April 2014, 250,000 new Ordinary shares were issued at 8p per share in settlement of £20,000 of fees owed to Spur Lodge Limited in respect of fees for Tony Reeves (the Company's Non-Executive Chairman) and 162,500 new Ordinary shares were issued at 8p per share in settlement of £13,000 of company secretarial fees owed to Kitwell Consultants Limited (a company owned by Mike Hirschfield).

On 24 April 2014, 6,250,000 new ordinary shares were issued for proceeds of £500,000.

Following these issues, and as at 30 May 2014, there are 154,437,500 Ordinary Shares of 0.1 pence each in issue.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR WGUWAAUPCGCU
Date   Source Headline
27th Mar 20174:06 pmRNSFinal Results
16th Mar 201710:30 amRNSShareholder update
28th Feb 201711:50 amRNSResignation of Nominated Adviser
28th Feb 201711:50 amRNSUpdate on Suspension
24th Feb 20174:18 pmRNSSuspension - Cloudtag Inc.
24th Feb 20172:05 pmRNSSecond Price Monitoring Extn
24th Feb 20172:00 pmRNSPrice Monitoring Extension
24th Feb 20177:00 amRNSFundraise and Notice of Resignation of Nomad
16th Feb 20175:31 pmRNSCorrection: Conversion of £0.1m Loan Notes
16th Feb 20171:28 pmRNSConversion of £0.1 million Loan Notes
15th Feb 20172:02 pmRNSConversion of £0.3 million Loan Notes
2nd Feb 20177:00 amRNSConversion of £0.4 million Loan Notes
25th Jan 20177:00 amRNSChange of Registered Office
17th Jan 20174:31 pmRNSExercise of Warrants - Receipt of Gross Proceeds
17th Jan 20177:00 amRNSConversion of Loan Notes and Exercise of Warrants
4th Jan 20177:00 amRNSConversion of £0.25 million Loan Notes
3rd Jan 201710:13 amRNSFurther re Tranche 2 Notes
3rd Jan 20177:00 amRNSFurther re Tranche 2 Notes
22nd Dec 20163:17 pmRNSClarification in respect of L1 warrant pricing
22nd Dec 20162:48 pmRNSClarification in respect of L1 warrant pricing
21st Dec 20165:47 pmRNSConversion of £0.7 million Loan Notes
19th Dec 20162:35 pmRNSTranche 2 Notes
16th Dec 20167:30 amRNSRestoration - Cloudtag Inc
15th Dec 20165:37 pmRNSUpdate and Restoration of Trading
12th Dec 20161:26 pmRNSResult of EGM
9th Dec 20165:48 pmRNSConversion of £1.15 million Loan Notes
9th Dec 20163:32 pmRNSSuspension - Cloudtag Inc.
7th Dec 20163:05 pmRNSMovement in Share Price
5th Dec 20163:24 pmRNSMovement in Share Price
1st Dec 20162:10 pmRNSHolding(s) in Company
1st Dec 201612:54 pmRNSHolding(s) in Company
28th Nov 20167:00 amRNSAmendment to Funding Agreement
25th Nov 20167:00 amRNSAgreement Signed with US Sales & Marketing Partner
24th Nov 20167:00 amRNSPosting of Circular
23rd Nov 20167:00 amRNSConversion of £600,000 Loan Notes
21st Nov 201610:54 amRNSAppointment of David He
17th Nov 20162:05 pmRNSSecond Price Monitoring Extn
17th Nov 20162:00 pmRNSPrice Monitoring Extension
14th Nov 20163:38 pmRNSConversion of £700,000 Loan Notes
10th Nov 20167:00 amRNSReceipt of Funds and Issue of Notes
8th Nov 20162:05 pmRNSSecond Price Monitoring Extn
8th Nov 20162:00 pmRNSPrice Monitoring Extension
7th Nov 20164:37 pmRNSFundraising and Update
14th Oct 20163:40 pmRNSExercise of Warrants
4th Oct 20169:19 amRNSExercise of Warrants
27th Sep 20161:01 pmRNSFundraise of £550,000 & Exercise of Warrants
27th Sep 20167:00 amRNSProposed Subscription of £550,000
21st Sep 20167:00 amRNSAppointment of Chief Business Development Officer
12th Sep 20167:00 amRNSOperational Update and Placing to Raise £500,000
5th Sep 201611:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.